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      Transplantation of dopaminergic precursors (DPs) is a promising therapeutic 
strategy of Parkinson’s disease (PD). However, limited cell source for dopaminergic 
precursors has become a major obstacle for transplantation therapy. In the first part of 
the study, we demonstrated that Foxa2 is superior to Lmx1a in inducing dopaminergic 
neuronal differentiation from induced neural progenitor cells (iNPCs). Based on the 
results above and some other published results, our group demonstrated that mouse 
fibroblasts can be reprogrammed into induced dopaminergic precursors (iDPs) through 
ectopic expression of transcription factors Brn2, Sox2 and Foxa2(1). In the current study, 
we hypothesized that similar strategy can be applied to generate human iDPs for future 
cell therapy of PD. We overexpressed transcription factors Brn2, Sox2 and Foxa2 in 
human fibroblasts and observed formation of neurospheres in the cultures. Subsequent 
characterization of the precursor colonies confirmed the generation of human induced 
dopaminergic precursors (hiDPs). These hiDPs were capable of self-renewal, proliferate, 
and differentiation. The hiDPs demonstrated high co-positive rate of midbrain neural 
progenitor markers DCX, Corin and neural progenitor marker Nestin by immunostaining. 
More importantly, the hiDPs also expressed high levels of ventral mesencephalon 
related neural progenitor marker genes such as Lmx1a, NIKX6.1, Corin, Otx2 and 
Mash1. After differentiation, those cells exhibited significantly higher levels of major 





Lmx1B and VMAT2. Together, these results suggest that human iDPs can be generated 
by direct reprogramming of fibroblasts. These human iDPs may serve as a safe and 
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CHAPTER 1: INTRODUCTION 
 
      Since the application of nuclei transfer technique which demonstrates the 
multipotency of differentiated cells, scientists have made great effort to optimize the 
reprogramming strategy to increase the safety and efficiency of conversion(2-6). The 
ultimate purpose is to provide sufficient cells for transplantation therapy or to build 
appropriate disease models for further study. 
      Parkinson’s disease (PD) is among the most prevalent neurodegenerative disorders 
which affects 1-2% of the population over 70 years old(7, 8). Key symptoms of PD result 
from loss of dopaminergic neurons in the substantia nigra, including rigidity, 
bradykinesia, resting tremor and postural instability(9). In later stages of the disease, 
pathological cell death occurs in the midbrain, basal forebrain and neocortex. This 
progressive brain-wide degeneration is also associated with the onset of dementia, 
autonomic dysfunction, and severe postural instability. Even though most of the patients 
with PD are sporadic, there are still 15% of the patients having family history and 5-10% 
inherit in a monogenic fashion(10, 11). Studying Parkinson related gene mutations could 
also help us understand better the pathogenesis of PD. To date, at least 23 loci and 19 
parkinsonism-causing genes have been identified by scientists. Familial PD has been 
linked to heritable autosomal dominant, recessive and X-linked mutations.  Autosomal-
dominant mutations in SNCA(12), PARK3(13), UCHL1(14), LRRK2(15), NR4A2(16), 
GIGYF2(17, 18), HTRA2(19), VPS35(20), EIF4G1(21), TMEM230(22), CHCHD2(23) 
and RIC3(24), as well as, autosomal-recessive mutations in PRKN(25), PINK1(26), 
ATP13A2(27), PARK7(28), FBXO7(29), DNAJC6(30), SYNJ1(31), PLA2G6(32) and 
VPS13C(33) have been implicated in the onset and progression of PD. Recently, 
PARK10(34), PARK16(35) and PARK12(17) with X-linked inheritance have also been 





incurable to date, existing pharmaceutical and surgical treatments such as L-3, 4-
dihydroxyphenylalanine (L-DOPA), dopamine receptor agonists and deep brain 
stimulation (DBS) can only ameliorate symptoms and signs. None of these therapeutic 
approaches can cure or even reverse the development of disease(36, 37). Besides, 
although initially beneficial, the effectiveness of the above pharmaceutical and surgical 
treatments declines throughout disease progression. The development of stem cell 
based therapeutic approach brought hope of curing PD by replacing lost neurons, 
compensating their function and preventing further neuronal dysfunction and death. 
Compared to the compensatory dopamine provided temporarily by medications, 
dopamine-producing neurons derive from transplanted neural stem cells can produce 
dopamine inside patients’ substantia nigra and enhance the recovery of dopamine 
signaling in damaged neural circuitry. It has already been proved that transplanted 
embryonic dopamine neurons can significantly improve motor function in early onset PD 
patients(38). Besides, neural stem cells are more suitable PD models compared to other 
somatic cells(39-42). There are two leading theories as to how these transplanted neural 
stem cells provide therapeutic potential. One is that those cells may directly replace 
damaged neurons, the other one is those cells can indirectly protect neurons after 
injection through release of neurotrophic and immunomodulatory factors(43-46). 
      For the applications, it would be more desirable to generate proliferative induced 
neural progenitor/stem cells (iNPCs/iNSCs), instead of neurons with no proliferation 
ability, from somatic cells(47-51). However, even though iNPCs hold great potential in 
regenerative medicine, they have an intrinsic potential for multi-lineage differentiation 
into astrocytes, oligodendrocytes, and dozens of neuronal subtypes(47, 49, 50, 52-54). 
The directed differentiation of these precursors into a highly defined state for therapeutic 





understood. Therefore, the induction of restricted neural progenitors might be better 
suited to regenerate specific populations of neural cells following degeneration(55). Our 
initial studies have shown that skin fibroblasts can be successfully converted into 
induced neural progenitors (5F-iNPCs) by a set of five transcription factors, including 
Brn2, Sox2, TLX, Bmi1 and c-Myc (51). However, the dopaminergic differentiation 
efficiency of 5F-iNPCs in response to sonic hedgehog (SHH)/fibroblast growth factor 8 
(FGF8) stimulation remains low (<5%). Therefore, we kept on looking for more superior 
strategy. 
      Recently, several different research groups including ours have lay the focus on how 
to directly reprogram somatic cells to functional induced dopaminergic 
progenitors/precursors (iDPs)(1, 56, 57). The major potential advantage is that iDPs are 
restricted to dopaminergic neuronal lineage during the process of differentiation. Our lab 
has already successfully generated mouse iDPs through direct reprogramming(1). 
However, whether this strategy can be successfully applied on human cells is still 
unclear. We hypothesized that similar strategy can be applied to generate human iDPs 
for future cell therapy of PD. The transition from mouse to human cells is an essential 
step before this strategy can be used on real patients. This study would focus more on 












CHAPTER 2: METHODS 
 
2.1 Cell preparation, retroviral packaging, infection and direct reprogramming.      
 
      Human skin fibroblasts were isolated from the left leg of a female fetus aged 20 
weeks, which was obtained from elective aborted specimens following completion of the 
abortion procedure through collaborative works with the Birth Defects Research 
laboratory at University of Washington. The protocol is in compliance with all relevant 
state and federal regulations and is approved by the University of Nebraska Medical 
Center (UNMC) Institutional Review Board (IRB#: 123-02-FB). Fibroblasts were cultured 
in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 1×Non-Essential 
Amino Acid, 50U/ml penicillin, 50μg/ml streptomycin at 37 °C in a 5% CO2 humidified 
atmosphere. Fibroblasts were used within passage 2–5 to avoid replicative senescence. 
Human Brn2 ORF, Foxa2 ORF and Sox2 ORF were cloned into pMXs-retroviral vectors 
respectively (Cellbiolabs, RTV-010). Retroviruses (pMXs) were generated with Plat-GP 
packaging cells. Plat-GP cells were seeded at 3.2-3.6×106 cells per 100mm poly-L-
ornithine (PLO) /laminin coated dish. 24 hours after seeding, 10μg DNA of pMXs-based 
retroviral vectors encoding human Sox2, Brn2 and Foxa2 together with 5μg DNA of the 
vesicular stomatitis virus envelope G protein (VSV-G) expressing packaging plasmid 
(pcMV-VSV-G) were introduced into Plat-GP cells using Lipofectamine LTX & PLUS™ 
transfection reagent (Invitrogen). To be specific, dilute 15μg DNA in 1ml Opti-MEM® 
Medium, then add 15μl PLUS™ Reagent. After 5 minutes incubation at room 
temperature, add 15μl Lipofectamine® LTX Reagent. Add DNA-lipid complex to cells 
after 5 minutes incubation at room temperature. The medium was replaced with 5.5ml of 
DMEM containing 5% FBS 24h after transfection. Human fibroblasts (hFbbs) were 
seeded at 2-3 ×105 cells per 35mm culture dish. At 48h and 72h post-transfection, 5ml 





0.45μm cellulose acetate filter and collected. Equal volumes of the supernatants from 3 
dishes were mixed and supplemented with 10μg/ml polybrene. Human fibroblasts were 
incubated in virus/polybrene-containing supernatants overnight. The medium was 
changed 72 hours after infection to NeuroCult® human NSC Basal (Stem Cell 
Technologies, Inc., Vancouver, BC V5Z 1B3, Canada) Medium supplemented with 
NeuroCult® human NSC Proliferation Supplements (Stem Cell Technologies, Inc.), 
20ng/ml basic fibroblast growth factor (bFGF, BioWalkersville), 20ng/ml epidermal 
growth factor (EGF, BioWalkersville) and 5μg/ml heparin (Sigma-Aldrich, St. Louis, MO). 
After 10-21 days, the predicted human iDP colonies were monitored by fluorescence 
microscope.  
 
2.2 Quantitative Real-Time reverse transcription polymerase chain reaction.  
 
      Total mRNA was isolated with TRIzol Reagent (Invitrogen) and RNeasy Mini Kit 
(QIAGEN Inc., Valencia, CA) using a protocol provided by the manufacturer. The 
reverse transcription was performed using Transcription 1st Strand cDNA Synthesis Kit 
(Roche, USA). The RT-PCR analyses for the detection of human neural stem cell-
specific mRNAs were performed using SYBR® Select Master Mix (Life Technologies, 
Los Angeles, CA) with 0.5μl of cDNA, corresponding to 1μg of total RNA in a 15μl final 
volume consisting of 7.5μl SYBR Green, 1.5μl H2O and 5.5μl oligonucleotide primer 
pairs (synthesized at Fisher) at 10μM. PCR program: 1) 50 °C for 2 minutes, 2) 95 °C for 
2 minutes; 3) 95 °C for 15 seconds, 4) specific annealing temperature for 15 seconds 
and 5) 72 °C for 1minutes. Steps 2 to 4 were repeated 40 times. All samples were 






2.3 Immunocytochemistry.  
 
      The cultured cells were fixed in 4% formaldehyde for 15 minutes at room 
temperature, and then washed with PBS for 3 times, 10 minutes per time. The fixed cells 
were simultaneously permeabilized and blocked with 0.2% Triton X-100 and 5% horse 
serum in PBS for 30 minutes at room temperature. Cells were incubated with primary 
antibodies as listed in Table 2 overnight at 4°C, and then washed with PBS for 3 times 
and incubated for 2h at room temperature with secondary antibodies (Table 2). 
Fluorescent images were obtained using a Zeiss 710 Confocal Laser Scanning 
Microscope (Carl Zeiss, Oberkochen, Germany). 
 
2.4 Cell proliferation rate 
 
      The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega) was 
used to determine the number of viable cells in proliferation. To be specific, cells were 
seeded into 96-well tissue culture plates (Fisher scientific). The reagent MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] was 
added to the wells in the proportion of 20 µl per 100 µl medium. After the plates were 
incubated at 37°C for 1-4 hours, optical density (OD) 490 values were read and 
calculated with BioTek Gen5 data analysis software. 
 
2.5 Differentiation.  
 
      For neuronal differentiation, SHH/FGF8 dependent protocol was used: Cells were 
plated on PLO/laminin coated coverslips in 24-well plate with DMEM/F12 containing 1× 





(Peprotech) for 6 days, then switched to DMEM/F12 containing 1× N2, 1× B27, 0.2mM 
ascorbic acid (Sigma), 0.1mM β-mercaptoethanol, 1.0mM dibutyrylcAMP (Sigma), 
10ng/mL glial cell line-derived neurotrophic factor (GDNF) (Peprotech), and 10ng/mL 
brain-derived neurotrophic factor (BDNF) (Peprotech) for another 4-8 weeks. The 
medium was changed every 3 days.  
 
2.6 Statistical Analyses.  
 
      Statistical analyses were performed using GraphPad Prism 7.00 and IBM SPSS 
Statistics Version 22. The data presented are means with standard deviations unless 
specified otherwise. Normality of data was tested using the Shapiro-Wilk Test. 
Differences between groups were compared using the one-way ANOVA with Bonferroni 
correction for multiple comparisons unless specified. A P of < 0.05 was considered as 














CHAPTER 3: RESULTS 
 
3.1 Foxa2 is superior to Lmx1a in converting mouse iNPCs into neural progenitors 
with midbrain identity 
 
      The iNPCs (induced by 5 factors, including Brn2, Sox2, TLX, Bmi1 and c-Myc) were 
infected with retroviruses encoding Foxa2 or Lmx1a or both Foxa2 and Lmx1a 
respectively. The expression of Foxa2 and Lmx1a was engineered under the control of 
doxycycline (Dox) (Fig. 2A). Then we compared the growth rate of different cell lines 
(iNPCs, Lmx1a-iNPCs, Foxa2-iNPCs, Lmx1a-Foxa2-iNPCs) at day 1, 3, 5 and 7 (Fig. 
2B). Dox negative groups were also tested as control. Our results showed that Lmx1a-
Foxa2-iNPCs cell line has the lowest cell growth rate at all the time points, followed by 
Foxa2-iNPCs and Lmx1a-iNPCs. iNPCs cell line demonstrated the most active 
proliferative activity.  
      iNPCs exhibited the highest level of neural progenitor markers Nestin, CD133 and 
Mushashi compared to other cell lines (Fig 1C-E). The difference was most significant 
between iNPCs and Lmx1a-Foxa2-iNPCs cell line (p<0.001). However, Lmx1a-Foxa2-
iNPCs expressed the highest levels of dopaminergic neuron proliferative progenitor cell 
markers Corin and Otx2, followed by Lmx1a-iNPCs (Fig. 1F, G). Foxa2-iNPCs 
expressed the highest level of Pitx3, which is another dopaminergic neuron proliferative 
progenitor marker, followed by Lmx1a-Foxa2-iNPCs (p<0.05, compared to iNPCs) (Fig. 
1H). After 6 weeks of differentiation in the presents of SHH and FGF8 stimulation, the 
differentiation efficiency of different cell lines into dopaminergic neurons was tested (Fig. 
2). PT-PCR was performed to identify the relative levels of tyrosine hydroxylase (TH) in 
the resulting cells after differentiation. Cells derived from Lmx1a-Foxa2-iNPCs cell line 
expressed the highest level of TH (p<0.001), followed by the cells derived from Foxa2-





and Foxa2 also exhibited the highest level of mature neuronal marker MAP2 (p<0.0001), 
followed by cells overexpressed only Foxa2 (p<0.01), Lmx1a and iNPCs (Fig. 2C). More 
iNPCs with overexpression of Foxa2 differentiated into dopaminergic (DA) neurons 
(3.6% TH and MAP2 positive cells) compared to those overexpressed Lmx1a (1.5% TH 
and MAP2 positive cells) according to the immunostaining results (Fig. 4). Cells from 
Foxa2-iNPCs expressed the highest level of another general neuronal marker Tuj1 
(p<0.0001), followed by Lmx1a-Foxa2-iNPCs and Lmx1a-iNPCs (p<0.01). The results of 
immunostaining are consistent with that of RT-PCR (Fig. 3). On the other hand, unlike 
cells from iNPCs cell line, cells from Lmx1a-Foxa2-iNPCs expressed much lower levels 
of glial-lineage related genes, such as astrocyte marker GFAP and S100β (Fig. 2 D, E). 
In sum, the number of TH, Tuj1 and MAP2 positive cells were ranked in the sequence of 
Lmx1a-Foxa2-iNPCs, Foxa2-iNPCs, Lmx1a-iNPCs and iNPCs. In contrast, the levels of 
GFAP positive cells were ranked in the sequence of iNPCs, Foxa2-iNPCs, Lmx1a-iNPCs 






Figure 1. Characteristics of iNPCs overexpress Lmx1a, Foxa2 or both Lmx1a and 
Foxa2. (A) Identification of the overexpression of Lmx1a, Foxa2 or both Lmx1a and 
Foxa2 in 5F iNPCs by RT-PCR; (B) The growth rate of different cell lines (iNPCs, 
Lmx1a-iNPCs, Foxa2-iNPCs, Lmx1a-Foxa2-iNPCs) at day 1, 3, 5 and 7; (C) 
Comparison of CD133 expression level between different cell lines; (D) Comparison of 
Nestin expression level between different cell lines; (E) Comparison of Mushashi 
expression level between different cell lines; (F) Comparison of Otx2 expression level 
between different cell lines; (G) Comparison of Corin expression level between different 
cell lines; (H) Comparison of Pitx3 expression level between different cell lines. *denotes 







Figure 2. Differentiation efficiency of different cell lines into neurons with 
dopaminergic neuron identity. (A) Comparison of TH expression level between 
different cell lines after 2-month differentiation by RT-PCR; (B) Comparison of Tuj1 
expression level between different cell lines after 2-month differentiation by RT-PCR; (C) 
Comparison of MAP2 expression level between different cell lines after 2-month 
differentiation by RT-PCR; (D) Comparison of GFAP expression level between different 
cell lines after 2-month differentiation by RT-PCR; (E) Comparison of S100β expression 
level between different cell lines after 2-month differentiation. Different cell lines include 
iNPCs, Lmx1a-iNPCs, Foxa2-iNPCs, Lmx1a-Foxa2-iNPCs. *denotes p < 0.05, **denotes 







Figure 3. Comparison of the percentage of TH and Tuj1 positive neurons after 
differentiation from different cell lines. (A) Expression of TH and Tuj1 in cells 
differentiated from different cell lines by immunostaining; (B) Percentage of TH or Tuj1 
positive cells differentiated from different cell lines. Different cell lines include iNPCs, 
Lmx1a-iNPCs, Foxa2-iNPCs, Lmx1a-Foxa2-iNPCs. *denotes p < 0.05, ***denotes 







Figure 4. Comparison of the percentage of TH and MAP2 positive neurons after 
differentiation from different cell lines. (A) Expression of TH and MAP2 in cells 
differentiated from different cell lines by immunostaining; (B) Percentage of TH or MAP2 
positive cells differentiated from different cell lines. Different cell lines include iNPCs, 
Lmx1a-iNPCs, Foxa2-iNPCs, Lmx1a-Foxa2-iNPCs. *denotes p < 0.05, **denotes 







Figure 5. Comparison of the percentage of Tuj1 and GFAP positive neurons after 
differentiation from different cell lines. (A) Expression of Tuj1 and GFAP in cells 
differentiated from different cell lines by immunostaining; (B) Percentage of Tuj1 or 
GFAP positive cells differentiated from different cell lines. Different cell lines include 
iNPCs, Lmx1a-iNPCs, Foxa2-iNPCs, Lmx1a-Foxa2-iNPCs. *denotes p < 0.05, **denotes 





3.2 Foxa2, Brn2 and Sox2 can convert human fibroblasts into neural progenitors 
with midbrain identity 
 
      Based on the results above and some other results that have already been 
published(1). Our lab initially examined the role of Foxa2 and two other known 
reprogramming factors Sox2 and Brn2 in the direct conversion of mouse somatic cells 
into dopaminergic neural progenitors and achieved success(1). Thereafter, whether this 
strategy can be applied on human somatic cells was tested. Human fetus fibroblasts 
were isolated and cultured. The fibroblasts were transfected with retroviruses encoding 
Brn2, Sox2 and Foxa2 following the schematic procedure in Fig. 6A. During day 10-21 
post-transfection, we observed the colony formation of cells (Fig. 6B). Eight colonies 
were obtained in total, however only three of them were confirmed to be expandable 
clones after subculture. PT-PCR was performed to identify the relative levels of Foxa2, 
Sox2 and Brn2 in the resulting cells after subculture. Only the cells (named hiDPs, 
human induced dopaminergic progenitors) from one of the three expandable clones 
retained high expression levels of Foxa2, Sox2 and Brn2 compared to the original 
human skin fibroblasts (hFbbs) (Fig. 6C). Cells from the other two expandable clones 
only expressed high levels of Sox2 and Brn2, indicating the failure of Foxa2 transfection. 
The hiDPs were characterized through the expression levels of several key neural 
progenitor marker genes in hiDPs and hFbbs by real-time RT-PCR analysis (the 
sequences of primer pairs were listed in Table 1). Importantly, the hiDPs expressed high 
levels of dopaminergic neuron proliferative progenitor cell markers, including Corin 
(Lrp4), Lmx1a, Otx2, Mash1, Pitx3 and Nkx6.1 (p<0.05, compared to hFbbs) (Fig. 7C). 
These genes were previously reported to specifically expressed in dopaminergic neuron 
proliferative progenitor cells(20,23,27,28). The hiDPs exhibited high co-positive 
expression of Corin and Nestin, at the rate of 91.22±7.19% (Fig. 7A, B). The cells also 





immunofluorescent staining (Fig.7A, B). These results suggest that fibroblasts could 
acquire the mesencephalic regional identity and dopaminergic neural fate through the 
forced over expression of transcription factors human Brn2, Sox2 and Foxa2. The 




Figure 6. Generation of human induced dopaminergic neuron progenitors. (A) 





clone formation at 20 dpi under microscope; (C) The overexpression of Sox2, Brn2 and 
Foxa2 in hiDPs derived from human fibroblasts. 
 
Figure 7. Characteristics of hiDPs. (A) Expression of DCX, Corin and Nestin in hiDPs 
cells by immunostaining; (B) Co-positive rate of Corin/Nestin and Corin/DCX; (C) The 
expression of a specific set of neural progenitor marker genes. GAPDH and human 
fibroblasts (hFbb) served as internal and negative control respectively. *denotes p < 
0.05, ***denotes p<0.001, ****denotes p<0.0001 compared to hFbbs. 
 
3.3 hiDPs express specific dopaminergic progenitor markers and has 
dopaminergic neuronal-restricted differentiation potential 
 
      We further validated whether the iDPs are dopaminergic neuronal lineage-restricted 
by differentiating the iDPs into neurons in the presence of SHH and FGF8 stimulation 





maturation. After 4-8 weeks of differentiation, we tested the differentiation efficiency of 
hiDPs into dopaminergic neurons (Fig. 8 and 9). The results demonstrated that the 
neurons derived from hiDPs expressed high levels of TH after 4-week and 8-week 
differentiation (compared to both hiDPs before differentiation and hFbbs), suggesting 
dopaminergic neuronal lineage-restricted fate for the iDPs (Fig. 8 and 9). They also 
exhibited significantly higher levels of major functionally relevant proteins in 
dopaminergic neurons, including TH, DAT, AADC, Lmx1b and brain-specific isoform of 
the vesicular monoamine transporter (VMAT2) compared to both the original hFbb cells 
and hiDPs before differentiation (Fig. 9). To be specific, after 8 weeks of differentiation, 
the level of TH, DAT and Lmx1b in cells from hiDPs were relatively higher than those 
after 4 weeks of differentiation. Additionally, about 91.28% of the Tuj1+ neurons are TH+ 
dopaminergic neurons. About 96.67% of the TH+ neurons are NeuN positive, about 
86.75% of the TH+ dopaminergic neurons are MAP2 positive neurons, indicating the 
mature neuron nature of the neurons derived (Fig. 8B). 
      Those results suggest that iDPs can effectively differentiate and generate mature 









Figure 8. hiDPs differentiate into neurons with dopaminergic neuron identity. (A) 
Expression of TH, VMAT2, AADC and neuron marker NeuN, MAP2 and Tuj1; (B) Co-






Figure 9. The expression of a specific set of dopaminergic neuron marker genes in 
cells differentiated from hiDPs. (A) The expression of TH, DAT, VMAT2, AADC, MAP2 
and LMX1B after 4 weeks of differentiation; (B) The expression of TH, DAT, VMAT2, 
AADC, MAP2 and LMX1B after 4 weeks of differentiation. *denotes p < 0.05, **denotes 
p < 0.01, ***denotes p<0.001, ****denotes p<0.0001 compared to hiDPs before 








CHAPTER 4:  DISCUSSION 
 
      PD is a movement disorder secondary to loss of dopaminergic neurons in the pars 
compacta region of the substantia nigra. Therefore, cell replacement therapy offers a 
potential means for curing this disease. Dopaminergic neuron progenitors from fetal 
ventral mesencephalon tissue have been transplanted into the striatum of PD patients 
with good results in several cases(58, 59). However, ethical concerns of using fetal 
tissues limited its use in the growing PD patient population. Direct reprogramming has 
been accepted as a safer and more efficient way to obtain desired type of cells(57). 
Several groups have previously proven that Sox2 and Brn2 are critical for the direct 
conversion of fibroblasts into iNPCs(49, 51, 52, 60, 61). By expressing defined transcript 
factors in addition to Brn2 and Sox2, we think it is possible to directly convert somatic 
cells to neuronal lineage-restricted progenitors. Since the cooperation of SHH-Foxa2 
and Wnt1-Lmx1a pathways plays a significant role in the development of dopaminergic 
progenitors and DA neurons, we studied the role of Foxa2 and Lmx1a in promoting the 
differentiation of mouse iNPCs (5 factors) into DA neurons(62). 
      The fact that Lmx1a-Foxa2-iNPCs cell line has the lowest proliferation rate and 
expresses low level of neural progenitor markers is consistent with its tendency of 
differentiation. Foxa2-iNPCs and Lmx1a-iNPCs also exhibit lower proliferation rate and 
lower level of neural progenitor markers compared to iNPCs. In contrast, Lmx1a-Foxa2-
iNPCs, followed by Foxa2-iNPCs and Lmx1a-iNPCs, express higher levels of 
dopaminergic neuron proliferative progenitor cell markers compared to iNPCs, indicating 
some mesencephalic dopaminergic progenitor characteristics of these cells. After 
differentiation, cells derived from Lmx1a-Foxa2-iNPCs are the most superior in DA 
neuron differentiation efficiency, followed by cells from Foxa2-iNPCs, then Lmx1a-





indicating the critical function of Foxa2 and Lmx1a in DA neuron development. iNPCs 
that overexpress both Foxa2 and Lmx1a demonstrate a superior DA neuron 
differentiation efficiency compared to iNPCs and iNPCs that only overexpress Foxa2 or 
Lmxa2. Recent evidence has indicated that Foxa2 is an upstream factor and can 
positively regulate Lmx1a/b in SHH and Wnt1 signaling which is significant in midbrain 
DA neuron development(62). Our results also suggest that Foxa2 is superior to Lmx1a in 
directing the differentiation from progenitors to DA neurons. Therefore, Foxa2, along with 
the other 2 known reprogramming factors Sox2 and Brn2, was used for further study to 
develop mouse and human fibroblasts into dopaminergic progenitors.  
      Recently, Kim and colleagues demonstrated that mouse fibroblasts can be directly 
reprogrammed to functional and proliferating midbrain induced dopaminergic 
progenitors/precursors (iDPs) by the induction of Sox2, Klf4, c-Myc and Oct4 and further 
culture in presence of SHH and FGF8(57). After differentiation, the reprogrammed iDPs 
yielded a higher proportion of TH+/TuJ1+ dopaminergic neurons than iNPCs (<3%), 
especially with the co-inhibition of Jak and Gsk3β (57.2±7.2%). Based on the above and 
some other experimental results, our group optimized the reprogramming strategy and 
proved that mouse fibroblasts could be directly converted into iDPs with forced ectopic 
expression of three transcription factors (Brn2, Sox2 and Foxa2)(1). The derived mouse 
iDPs expressed high levels of specific neural progenitor markers and midbrain specific 
markers including Corin, Otx2 and Lmx1a. The major advantage was that iDPs were 
restricted to dopaminergic neuronal lineage during the process of differentiation. After 
differentiation, more than 90% of the Tuj1+ neurons are TH+ dopaminergic neurons. The 
efficiency of differentiation remained high even in absence of the pre-patterning 
morphogens SHH and FGF8, strongly suggesting the dopaminergic neural properties of 





grafted iDPs differentiated into mature DA neurons rather than astrocytes without tumor 
formation. Based on the preliminary work, we conducted direct reprogramming by 
combining Sox2, Brn2, Foxa2 and successfully converted human fibroblasts into hiDPs. 
The expression of TH, a dopamine processing enzyme, and vesicular transporters of 
dopamine indicate the hiDPs we obtained acquired functional dopamine synthesis and 
processing mechanisms. Moreover, differential gene expression analyses confirmed 
broad upregulation of neurogenic- and dopamine-related RNA transcripts. The high co-
positive rate of Tuj1 and TH, as well as TH and MAP2/TH and NeuN, supports the high 
efficiency of dopaminergic neuron specific differentiation from the hiDPs.  TH is an 
enzyme involved in the synthesis of dopamine and norepinephrine (NE), which generally 
used in the field as a marker for dopaminergic neurons. Tuj1, MAP2 and NeuN are 
general neuronal markers. MAP2 is more in the cell soma, NeuN is more in the nucleus, 
while Tuj1/beta III tubulin is more in the processes. MAP2 and NeuN are generally more 
mature markers than Tuj1. The dopaminergic neuron-like cells we derived from hiDPs 
also overexpress DAT, AADC, Lmx1B and VMAT2. DAT, AADC, Lmx1B and VMAT2 are 
widely used dopaminergic neuron markers(63-65). DAT is a transmembrane transporter 
that controls the re-uptake of extracellular dopamine into presynaptic neurons. Lmx1B is 
a transcription factor involved in a number of processes during dopaminergic neuron 
development. The presence of aromatic L-amino acid decarboxylase (AADC) 
determines the ability of the neuron to make dopamine from L-DOPA (differential 
expression of dopaminergic cell markers in the adult zebrafish). The vesicular 
monoamine transporter 2 (VMAT2) has been suggested to be an excellent marker of 
presynaptic dopaminergic nerve terminals(66). Overexpression of these markers 





      The hiDPs we developed have great potential in basic research and clinical 
application. Firstly, those cells are more appropriate PD models given the pathology of 
PD. They can better simulate those cells primarily affected under real disease 
circumstance and can help us understand better the pathology of certain gene 
mutations. To date, several groups have used iPSCs derived dopaminergic neurons with 
common PD mutations to study PD onset in living cells and obtained significant findings 
(67). 
      Moreover, hiDPs generated from direct reprogramming can provide a safe cell 
source for the cell replacement therapy. Skin fibroblasts are relatively easy to obtain 
from patients. Besides, hiDPs derived from fibroblasts provide a source of autologous 
tissue for grafting. Without the potential for immune rejection, hiDPs can be a safe and 
effective cell-based treatment for PD. In addition, hiDPs circumvent the limitations 
including neoplasia, low efficiency of differentiation and lack of the potential to self-
renew(68). According to our results, the efficiency of differentiation from hiDPs to 
dopaminergic neurons is above 80% with certain differentiation protocols. In addition, 
hiDPs, like iPSCs, benefit from its capacity of self-renewal and can serve as targeted 
cells for gene editing technologies(69). Last but not least, hiDPs and the neurons they 
differentiated into can be used as excellent tools for drug screening and helpful in finding 
and evaluating new drugs. In sum, derivation of hiDPs may be a promising approach 
that can be applied therapeutically to restore function in patients with PD, as well as 
tools for PD mechanism study and drug screening.  
      Some shortages of our study are: 1) the lack of in vivo study in a neurotoxin 1-
methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of PD or other PD 
mouse models; 2) the lack of electrophysiological study of possible functional membrane 





      In this study, with the same reprogramming strategy, we successfully converted 
human fibroblasts directly into human iDPs by overexpressing defined transcription 
factors Foxa2/Brn2/Sox2 and confirmed our hypothesis. The hiDPs we developed also 
express high levels of midbrain progenitor specific markers including Corin (Lrp4), 
Lmx1a, Otx2, Mash1, Pitx3 and Nkx6.1. We believe the generation of hiDPs is a new 
and promising approach of cell-based treatment strategy for PD, as well as a safer and 
reliable way to build PD cell models. Expansion of the engineered hiDPs may be able to 





















Table 1. Sequences of primer pairs 
hTH Forward 5-AGCTGTGAAGGTGTTTGAGACGT-3 
 Reverse 5-TCGAGGCGCACGAAGTACT-3 
hAADC Forward 5-GGGACCACAACATGCTGCTC-3 
 Reverse 5-CCACTCCATTCAGAAGGTGCC-3 
hPitx3 Forward 5-GAGCTATGCAAAGGCAGCTT-3 
 Reverse 5-AGTTGAAGGCGAATGGAAAG-3 
hLmx1b Forward 5-AACTGTACTGCAAACAAGACTACC-3 
 Reverse 5-TTCATGTCCCCATCTTCATCCTC-3 
hDAT Forward 5-GTATGCTCTGATGCCGTCT-3 
 Reverse 5-GTATGCTCTGATGCCGTCT-3 
hVMAT2 Forward 5-CTTTGGAGTTGGTTTTGC-3 
 Reverse 5-GCAGTTGTGATCCATGAG-3 
hMAP2 Forward 5-CAGGAGACAGAGATGAGAATTCCTT-3 
 Reverse 5-GTAGTGGGTGTTGAGGTACCACTCTT-3 
hNkx6.1 Forward 5-GGACTGCCACGCTTTAGCA-3 
 Reverse 5-TGGGTCTCGTGTGTTTTCTCT-3 
hMash1 Forward 5-CCCAAGCAAGTCAAGCGACA-3 
 Reverse 5-AAGCCGCTGAAGTTGAGCC-3 
hALDH1A1 Forward 5-GCACGCCAGACTTACCTGTC-3 
 Reverse 5-CCTCCTCAGTTGCAGGATTAAAG-3 
hFoxa2 Forward 5-CTTCAAGCACCTGCAGATTC-3 
 Reverse 5-AGACCTGGATTTCACCGTGT-3 
hSox2 Forward 5-CCCACCTACAGCATGTCCTACTC-3 





hBrn2 Forward 5-GGAGTAGGGACACTCCACCA-3 
 Reverse 5-CAGGAAGCTGCATTTTGTG-3 
hGAPDH Forward 5-CGACCACTTTGTCAAGCTCA-3 
 Reverse 5-TCTACATGGCAACTGTGAGGA-3 
mPitx3 Forward 5-TGCGCTGTCGTTATCGGAC-3 
 Reverse 5-GGTAGCGATTCCTCTGGAAGG-3 
mLmx1a Forward 5-ACGGCCTGAAGATGGAGGA-3 
 Reverse 5-CAGAAACCTGTCCGAGATGAC-3 
mCorin Forward 5-TGGAGGTGCCTATCAGAGAGA-3 
 Reverse 5-GTGAGATCCAGTAACGCATTCA-3 
mOtx2 Forward 5-TATCTAAAGCAACCGCCTTACG-3 
 Reverse 5-AAGTCCATACCCGAAGTGGTC-3 
mGFAP Forward 5-CTGGAACAGCAAAACAAGGCGCTGG-3 
 Reverse 5-TCCAGCCTCAGGTTGGTTTCATC-3 
mNestin Forward 5-CCCTGAAGTCGAGGAGCTG-3 
 Reverse 5-CTGCTGCACCTCTAAGCGA-3 
mCD133 Forward 5-TGTTGTTGGCGCAAATGTGG-3 
 Reverse 5-TGTTCCTTGAGCAGATAGGGA-3 
mFoxa2 Forward 5-TCAACCACCCCTTCTCTATCAACAACC-3 
 Reverse 5-TGGGTAGTGCATGACCTGTTCGTAGG-3 
mGAPDH Forward 5-TCACCACCATGGAGAAGGC-3 
 Reverse 5-GCTAAGCAGTTGGTGGTGCA-3 
 





Primary antibody Isotype Dilution Source 
MAP2 Mouse IgG 1:1000 Millipore 
TH Rabbit IgG 1:500 abcam 
Tuj1 Mouse IgG 1:1000 Sigma 
GFAP Rabbit IgG 1:1000 DAKO 
Nestin Chicken IgY 1:1000 Novus biologicals 
Corin Mouse IgG 1:1000 R&D Systems  
DCX Goat IgG 1:1000 Santa Cruz  
NeuN Mouse IgG 1:1000 abcam 
AADC Rabbit IgG 1:1000 Invitrogen 
VMAT2 Mouse IgG1 1:1000 Novus biologicals 
Secondary 
antibody 
Isotype Dilution Source 
Alexa Fluor® 488  Goat anti-Rabbit Ig G 1:1000 Molecular Probes 
 Goat anti-Mouse Ig G  1:1000 Molecular Probes 
 Rabbit anti-Goat Ig G  1:1000 Molecular Probes 
 Rabbit anti-Mouse Ig G 1:1000 Molecular Probes 
 Donkey anti-Goat Ig G  1:1000 Molecular Probes 
Alexa Fluor® 594  Goat anti-Rabbit Ig G  1:1000 Molecular Probes 
 Donkey anti-Rabbit Ig 
G  
1:1000 Molecular Probes 
 Donkey anti-Mouse 
IgG 
1:1000 Molecular Probes 
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